Tumor Burden Measured by 18F-FDG PET/CT in Predicting Efficacy and Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma

Chimeric antigen receptor (CAR) T-cell therapy has exhibited promising clinical outcomes in treating relapsed/refractory (R/R) B-cell hematologic malignancies. Current studies have shown a close correlation between baseline tumor burden and therapeutic response in CAR-T cell therapy. However, the ro...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Ruimin, Tan Su Yin, Elaine, Wang, Linqin, Zhao, Xin, Zhou, Linghui, Wang, Guangfa, Zhang, Mingming, Zhao, Houli, Wei, Guoqing, Wang, Yiyun, Wu, Wenjun, Zhang, Yafei, Ni, Fang, Hu, Yongxian, Huang, He, Zhao, Kui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371710/
https://www.ncbi.nlm.nih.gov/pubmed/34422666
http://dx.doi.org/10.3389/fonc.2021.713577

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371710/
https://www.ncbi.nlm.nih.gov/pubmed/34422666
http://dx.doi.org/10.3389/fonc.2021.713577

Ejemplares similares